HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Traditional Chinese Medicine

682.838

+20.8153.14%

Number of Gainers:6

Number of Losers:4

Number of Flat:1

PE:- -

High:687.197

Open:662.868

Low:662.868

Close:662.023

Volume:51.56M

Turnover:228.38M

Market Cap:70.23B

Float Cap:48.26B

Loading ...

China's Zhongzhi Pharmaceutical H1 Revenue Falls 10%

PuraPharm FY26 H1 Net Loss Narrows 34.7% to Hk$14.24 Million; Revenue Falls 7.3% to Hk$159.67 Million

Zhongzhi Pharm Posts Interim Results with 3.79% Rise in Net Profit Attributable to Shareholders

Zhongzhi Pharma FY26 H1 Profit Attributable to Owners Rises 3.8% to RMB 9.1 Million; Revenue Falls 10.3% to RMB 790 Million

Zhongzhi Pharmaceutical Holdings H1 Net Income Attributable RMB 9.1 Million

THOMSON REUTERS

Consun Pharma FY26 H1 Profit Attributable to Shareholders Rises 19.5% to RMB 595.31 Million; Revenue Increases 13.8% to RMB 1.78 Billion

Consun Pharmaceutical Declares Interim Dividend of HKD 0.38 Per Share

Singapore's Thomson Medical Group FY Revenue Rises on Singapore Strength, Malaysia Oncology Contribution

CONSUN PHARMA Sets October Date for Interim Dividend Payout

CONSUN PHARMA Posts 19.5% Profit Growth in First-Half Results, Renal Product Line Up 18.1%

GPHL Hosts Global Investment Conference in Singapore, Launches WALOVI International Headquarters

BAIYUNSHAN PH Gets Nod for Norepinephrine Bitartrate Injection Consistency Assessment

Hong Kong Stock Flash | Baiyunshan (00874) Drops Nearly 6% After Results, Net Profit Falls 16.7% in H1 Due to Higher R&D Spending

Guangzhou Baiyunshan Pharma's Profit Falls 17% in H1

MT Newswires Live

BAIYUNSHAN PH Reports Interim Results with Net Profit Attributable to Shareholders of Approximately RMB 2.096 Billion, Down 16.7% Year-on-Year

Modern Chinese Medicine Group Flags Expected Interim Loss of Approximately RMB 25.9 Million

Modern Chinese Medicine Expects RMB 25.9 Million H1 Net Loss vs RMB 2.5 Million Profit a Year Earlier

Modern Chinese Medicine Group Co - Expects Net Loss of Rmb25.9 Mln for Six Months Ended June 2026

THOMSON REUTERS

Modern Chinese Medicine Group Co - Hy Net Loss Mainly Due to Increased Promotion, Marketing, Research and Development Expenses

THOMSON REUTERS

Luye Pharma's Vaccine for Cervical Precancerous Lesions to Enter Phase II Trial

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://nz.tigrwd.com/stock/BK1606/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","market":"HK","secType":"PLATE","nameCN":"Traditional Chinese Medicine","latestPrice":682.8379,"timestamp":1787731681268,"preClose":662.02264,"halted":0,"volume":51557413,"delay":0,"changeRate":0.031442,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":20.815247,"latestTime":"08-26 16:00:00","open":662.8682,"high":687.19727,"low":662.8682,"amount":228377255,"amplitude":0.03675,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787794200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787707800000,1787716800000],[1787720400000,1787731200000]],"pbRate":0.685693,"peRate":12.142836,"turnoverRate":0.003302,"increases":6,"decrements":3,"flats":2,"marketCap":70226910208,"floatMarketCap":48255533568},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","high":687.19727,"amplitude":0.03675,"preClose":662.02264,"low":662.8682,"pbRate":"0.685693","latestPrice":682.8379,"volume":51557413,"delay":0,"open":662.8682,"prevYearClose":830.6915,"prevWeekClose":670.499,"prevMonthClose":681.608,"prevQuarterClose":629.733,"fiveDayClose":654.751,"twentyDayClose":685.472,"sixtyDayClose":737.007,"secType":"PLATE","market":"HK","turnoverRate":0.003302,"peRate":12.142836,"marketCap":70226910208,"floatMarketCap":48255533568,"timestamp":1787731681268,"nameCN":"Traditional Chinese Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1606\",,,,undefined,":{"bkCode":"BK1606","up":6,"down":4,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1606\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662715194","title":"China's Zhongzhi Pharmaceutical H1 Revenue Falls 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715194","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715194?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:36","pubTimestamp":1787744170,"startTime":"0","endTime":"0","summary":"China's Zhongzhi Pharmaceutical H1 revenue falls 10%OverviewChina pharmaceutical maker's half-year revenue fell 10.3% yr/yrProfit attributable to owners rose 3.8% yr/yrGross profit and margin declined","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL1N44N0G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","01681","03692","BK1600","BK1593","BK1589","BK1515","BK1606","BK1191","03737","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715196","title":"PuraPharm FY26 H1 Net Loss Narrows 34.7% to Hk$14.24 Million; Revenue Falls 7.3% to Hk$159.67 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715196","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715196?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:35","pubTimestamp":1787744109,"startTime":"0","endTime":"0","summary":"PuraPharm FY26 H1 net loss narrows 34.7% to HK$14.24 million; revenue falls 7.3% to HK$159.67 millionPuraPharm posted revenue of HK$159.67 million, down 7.3% year over year, for the six months ended J","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL5fjnwB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01498","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132103208","title":"Zhongzhi Pharm Posts Interim Results with 3.79% Rise in Net Profit Attributable to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=1132103208","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132103208?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:32","pubTimestamp":1787743935,"startTime":"0","endTime":"0","summary":"Zhongzhi Pharm (03737) has announced its interim financial results for the six months ended June 30, 2026, reporting a total revenue of RMB 790 million, a year-on-year decline of 10.28%.During the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","03737","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715347","title":"Zhongzhi Pharma FY26 H1 Profit Attributable to Owners Rises 3.8% to RMB 9.1 Million; Revenue Falls 10.3% to RMB 790 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715347","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715347?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:25","pubTimestamp":1787743504,"startTime":"0","endTime":"0","summary":"Zhongzhi Pharma FY26 H1 profit attributable to owners rises 3.8% to RMB 9.1 million; revenue falls 10.3% to RMB 790 millionZhongzhi Pharmaceutical posted revenue of RMB 789.96 million, down 10.3% from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL320KVG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03737","BK1606","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715871","title":"Zhongzhi Pharmaceutical Holdings H1 Net Income Attributable RMB 9.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715871","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715871?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:23","pubTimestamp":1787743438,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nPLXVL99JC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1606","BK1191","03737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662158997","title":"Consun Pharma FY26 H1 Profit Attributable to Shareholders Rises 19.5% to RMB 595.31 Million; Revenue Increases 13.8% to RMB 1.78 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662158997","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662158997?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:21","pubTimestamp":1787743318,"startTime":"0","endTime":"0","summary":"Consun Pharma FY26 H1 profit attributable to shareholders rises 19.5% to RMB 595.31 million; revenue increases 13.8% to RMB 1.78 billionConsun Pharmaceutical posted 1H 2026 profit attributable to equi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL4gkc8R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681","BK1606","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662976887","title":"Consun Pharmaceutical Declares Interim Dividend of HKD 0.38 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2662976887","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662976887?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:11","pubTimestamp":1787739080,"startTime":"0","endTime":"0","summary":"Consun Pharmaceutical declares interim dividend of HKD 0.38 per shareConsun Pharmaceutical declared an interim dividend of HKD 0.38 per share for the six months ended June 30, 2026.Shares trade ex-div","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL2SP6zl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1191","01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662794365","title":"Singapore's Thomson Medical Group FY Revenue Rises on Singapore Strength, Malaysia Oncology Contribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2662794365","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662794365?lang=en_us&edition=fundamental","pubTime":"2026-08-26 17:34","pubTimestamp":1787736889,"startTime":"0","endTime":"0","summary":"Singapore's Thomson Medical Group FY revenue rises on Singapore strength, Malaysia oncology contributionOverviewSingapore healthcare provider's FY2026 revenue grew 6.4% yr/yr, driven by regional expan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL1N44N0B0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1219","BK1606","A50.SI","BK1191","03309","BK1516","BK6511","BK6092","01681","BK1209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159396199","title":"CONSUN PHARMA Sets October Date for Interim Dividend Payout","url":"https://stock-news.laohu8.com/highlight/detail?id=1159396199","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159396199?lang=en_us&edition=fundamental","pubTime":"2026-08-26 12:46","pubTimestamp":1787719578,"startTime":"0","endTime":"0","summary":"CONSUN PHARMA (01681) has announced that it will distribute an interim dividend of HK$0.38 per share on October 8, 2026.According to the company's official statement, the dividend payment pertains to...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VIG","BK1191","BK1606","01681","BK4588","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193743871","title":"CONSUN PHARMA Posts 19.5% Profit Growth in First-Half Results, Renal Product Line Up 18.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193743871","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193743871?lang=en_us&edition=fundamental","pubTime":"2026-08-26 12:27","pubTimestamp":1787718448,"startTime":"0","endTime":"0","summary":"CONSUN PHARMA (01681) has announced its financial results for the six months ended June 30, 2026, reporting a revenue of RMB 1.785 billion, representing a year-on-year increase of 13.8%. The company...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1191","01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148661739","title":"GPHL Hosts Global Investment Conference in Singapore, Launches WALOVI International Headquarters","url":"https://stock-news.laohu8.com/highlight/detail?id=1148661739","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148661739?lang=en_us&edition=fundamental","pubTime":"2026-08-24 23:13","pubTimestamp":1787584384,"startTime":"0","endTime":"0","summary":"On August 24, the \"2026 GPHL International Cooperation Forum, Global Investment Conference, and WALOVI New Product Launch\" was grandly held at Resorts World Sentosa in Singapore. This event marked...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1197","BK1521","BK1606","600332","00874","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189898168","title":"BAIYUNSHAN PH Gets Nod for Norepinephrine Bitartrate Injection Consistency Assessment","url":"https://stock-news.laohu8.com/highlight/detail?id=1189898168","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189898168?lang=en_us&edition=fundamental","pubTime":"2026-08-24 16:36","pubTimestamp":1787560578,"startTime":"0","endTime":"0","summary":"BAIYUNSHAN PH (00874) has announced that its wholly-owned subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., has received the Drug Supplement Approval Notice from the National...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK1515","BK0070","BK1191","00874","BK0097","BK0175","BK0096","BK0183","BK0196","BK0239","BK1521","BK1606","BK0012","600332","BK0188","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150872953","title":"Hong Kong Stock Flash | Baiyunshan (00874) Drops Nearly 6% After Results, Net Profit Falls 16.7% in H1 Due to Higher R&D Spending","url":"https://stock-news.laohu8.com/highlight/detail?id=1150872953","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150872953?lang=en_us&edition=fundamental","pubTime":"2026-08-24 14:49","pubTimestamp":1787554167,"startTime":"0","endTime":"0","summary":"BAIYUNSHAN PH (00874) saw its shares tumble nearly 6% in Hong Kong trading following the release of its interim results, with the stock down 5.64% to HK$14.22 at the time of writing, on a turnover of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK0012","BK1191","KCAI","BK0183","VXUS","BK0097","600332","BK0239","BK0175","00874","BK1521","BK0028","BK0070","BK1606","BK0096","BK0196","BK1197","BK4585","BK0188","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661244886","title":"Guangzhou Baiyunshan Pharma's Profit Falls 17% in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2661244886","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661244886?lang=en_us&edition=fundamental","pubTime":"2026-08-24 09:04","pubTimestamp":1787533464,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical  posted an attributable net profit of 2.10 billion yuan for the first half of 2026, down 17% from 2.52 billion yuan a year earlier.Earnings per share rose to at 1.289 yuan from 1.548 yuan in the year-ago period, according to a Friday Hong Kong bourse filing.Revenue increased 0.61% year over year to 42.1 billion yuan from 41.8 billion yuan.The company proposed a cash dividend of 0.30 yuan per share, inclusive of tax, to all shareholders.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK1515","BK0070","BK1191","00874","FCA","BK0097","BK0175","BK0096","BK0183","BK0196","BK0239","BK1521","BK1606","BK0012","600332","BK0188","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149843220","title":"BAIYUNSHAN PH Reports Interim Results with Net Profit Attributable to Shareholders of Approximately RMB 2.096 Billion, Down 16.7% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1149843220","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149843220?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:50","pubTimestamp":1787320219,"startTime":"0","endTime":"0","summary":"BAIYUNSHAN PH (00874) has announced its interim results for 2026, with revenue reaching approximately RMB 42.091 billion, a modest increase of 0.61% year-on-year. Net profit attributable to...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK1521","BK1606","600332","BK0196","BK1515","BK0239","00874","BK0096","BK0183","BK1197","BK0012","BK0188","BK1191","BK0097","BK0028","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162352221","title":"Modern Chinese Medicine Group Flags Expected Interim Loss of Approximately RMB 25.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1162352221","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162352221?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:48","pubTimestamp":1787316495,"startTime":"0","endTime":"0","summary":"Modern Chinese Medicine Group (01643) has issued a profit warning, indicating that it expects to record a net loss of approximately RMB 25.9 million for the six months ending June 30, 2026.This...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01643","BK1606","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260445","title":"Modern Chinese Medicine Expects RMB 25.9 Million H1 Net Loss vs RMB 2.5 Million Profit a Year Earlier","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260445","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260445?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:06","pubTimestamp":1787314009,"startTime":"0","endTime":"0","summary":"Modern Chinese Medicine expects RMB 25.9 million H1 net loss vs RMB 2.5 million profit a year earlierModern Chinese Medicine Group expects a net loss of about RMB 25.9 million for the six months ended","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL4Wyl5n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1606","01643"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661412260","title":"Modern Chinese Medicine Group Co - Expects Net Loss of Rmb25.9 Mln for Six Months Ended June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661412260","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661412260?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:06","pubTimestamp":1787314004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0F8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1606","BK1191","01643"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260441","title":"Modern Chinese Medicine Group Co - Hy Net Loss Mainly Due to Increased Promotion, Marketing, Research and Development Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260441","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260441?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:06","pubTimestamp":1787314004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0F8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1606","01643","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661804252","title":"Luye Pharma's Vaccine for Cervical Precancerous Lesions to Enter Phase II Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2661804252","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661804252?lang=en_us&edition=fundamental","pubTime":"2026-08-21 13:36","pubTimestamp":1787290567,"startTime":"0","endTime":"0","summary":"Luye Pharma Group  said its LY01620 therapeutic mRNA vaccine for cervical precancerous lesions is set to enter a Phase II clinical trial in China.The trial will assess the candidate's safety and efficacy in patients with HPV16-positive high-grade cervical lesions, according to a Thursday Hong Kong exchange filing. Positive results from a Phase I study supported the move into Phase II, the company said in the filing.Shares of the company rose nearly 2% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1606","BK1583","02186","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}]}}